DPP4 and nasopharyngeal carcinoma: One study reported that while SGLT‐2 inhibitors were linked to a significantly lower risk of nasopharyngeal carcinoma (NPC) than other anti‐diabetic drug dipeptidyl peptidase 4 (DPP‐4) inhibitors, their association with overall HNC was not statistically significant [159].